Mercado mundial de tratamiento de la hemofilia A: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado

Según los Centros para el Control y la Prevención de Enfermedades (CDC) de Estados Unidos, la hemofilia afecta a aproximadamente uno de cada 5.617 nacimientos de varones vivos. En Estados Unidos, entre 30.000 y 33.000 hombres padecen hemofilia. El tipo grave de hemofilia A afecta a más de la mitad de los diagnosticados. La hemofilia A afecta a cuatro veces más personas que la hemofilia B. La hemofilia es un trastorno sanguíneo que afecta a personas de todas las razas y etnias. La hemofilia A, conocida comúnmente como hemofilia clásica, es una enfermedad hemorrágica genética causada por una falta de factor VIII en la sangre.

Data Bridge Market Research analiza que el mercado de tratamiento de la hemofilia A se valoró en USD 11.1 mil millones en 2021 y se espera que alcance los USD 17.77 mil millones para 2029, registrando una CAGR del 6,06% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Market Definition

Hemophilia A is an inherited bleeding disorder that causes blood to coagulate abnormally. People with hemophilia A will bleed more than usual after an injury, surgery, or dental procedure. Hemophilia A is caused by a protein called factor VIII being deficient. Replacement therapy is the most common treatment in which clotting factor VIII is gently dripped or injected into a vein. Emicizumab is presently the only licensed nonfactor therapy that helps with venous access difficulties, frequent bleeds, and other issues, according to the National Center for Biotechnology Information (NCBI). This treatment is also recommended to prevent bleeding in individuals taking inhibitors and having surgery. Following recent improvements, these new medicines show potential hemostatic qualities and enable considerable decreases in bleeding episodes in hemophilia patients with or without inhibitors. DDAVP (desmopressin acetate) is a synthetic version of vasopressin. This natural antidiuretic hormone helps to halt bleeding because of its clinical efficacy and safety and the availability of a concentrated formulation for intravenous and nasal administration.

Hemophilia A Treatment Market Dynamics

Drivers

• High prevalence rate of hemophilia across the globe

The rise in prevalence rate of hemophilia across the globe will act as a major driver that will result in the expansion of the market's growth rate. Patients with severe hemophilia require a frequent hemophilia treatment regimen to keep enough clotting factors in their bloodstream to avoid bleeds. Including a global study published in October 2021 by the World Federation of Hemophilia, there were 209,614 persons diagnosed with hemophilia worldwide, with 165,379 hemophilia A patients. Furthermore, patients who receive quality care are more likely to have fewer co-morbid diseases and have a decreased risk of serious bleeding. As a result, the ever-increasing number of patients has increased demand for haemophilia therapy, which will raise product adoption rates.

• Surging number of pediatric population

The increasing number of pediatric population is estimated to enhance the market's growth rate during the forecast period of 2022-2029. The prevalence of hemophilia is steadily rising among pediatric. Hemophilia is expected to affect one out of every 10,000 births, according to the World Federation of Hemophilia (WFH). Pediatric with hemophilia lack enough clotting factors in their blood as they cannot stop bleeding, necessitating the use of specific hemophilia medications to prevent excessive bleeding. A number of government and non-government groups are launching public awareness campaigns about the signs, diagnosis, and treatment of hemophilia in pediatrics. Furthermore, prominent industry players are focusing on developing innovative solutions to minimize the severity of hemophilia in pediatrics, hence accelerating market growth.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hemophilia A treatment market. Additionally, changing lifestyle of people and growing government favourable initiatives will result in the expansion of hemophilia A treatment market. Another significant factor influencing the growth rate of hemophilia A treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hemophilia A treatment market growth. BioMarin Pharmaceutical Inc. stated in 2021 that it had completed a large phase 3 gene therapy trial in adults with severe hemophilia A in the United States. Over the projection period, such continuous research and innovation initiatives are expected to boost market demand. As a result, the variables listed above are expected to boost product uptake in the country.

• New product launches

Over the projected period, new product launches by industry players in the hemophilia A treatment market are estimated to promote new market opportunities. For illustration, the European Commission granted Novo Nordisk marketing approval for 'Esperoct' in Europe in June 2019. Turoctocog alfa pegol, N8-GP, is marketed under the trade name Esperoct and is used to treat hemophilia A in adolescents and adults (congenital factor VIII deficiency). Furthermore, Roche Products India Pvt. Ltd released Hemlibra, a hemophilia A medication, in India in April 2019. Through Factor VIII inhibitors, it is suggested for preventative therapy of hemophilia A patients to reduce the frequency of bleeding episodes.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hemophilia A treatment market growth during the forecast period.

Restraints/Challenges

• High cost associated with the hemophilia A treatment

The high cost associated with the treatment will obstruct the growth rate of hemophilia A market during the forecast period of 2022-2029. According to the National Hemophilia Foundation, the average cost of hemophilia treatment is over USD 300,000 per year, which has a substantial influence on operation margins, especially in today's capitated reimbursement environment. Due to the high costs associated with clotting factor therapy, market expansion in emerging nations with comparatively low income levels may be impeded.

On the other hand, the lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the hemophilia A treatment market. Additionally, strict government policies and lack of awareness about the treatment will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This hemophilia A treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemophilia A treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

After von Willebrand disease, hemophilia A is the most common X-linked recessive condition and the most common inherited clotting factor deficiency. Males are more likely to be affected by hemophilia A, however, females can be impacted as well. Hemophilia A affects about 1 in every 5,000 new-born boys. Hemophilia A affects approximately 60% of people. Hemophilia affects people of all races and ethnic groups equally.

Hemophilia A treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Hemophilia A Treatment Market

Due to disruptions in the worldwide supply chain and logistics, the onset of the COVID-19 pandemic had a minor negative influence on the hemophilia treatment market. The impact of the coronavirus outbreak on the sector peaked in early 2020, when people with such disorders were more susceptible to infectious diseases and hence had a higher risk of contracting coronavirus. Several organizations, hospitals, and haematologists, on the other hand, were working hard to manage the COVID-19 public health issue. For instance, in response to the coronavirus outbreak, the American Society of Hematology established a forum for the exchange of useful, precise, and up-to-date information to aid haematologists. As a result, such approaches are predicted to aid in the restoration of treatment volume following the COVID-19 outbreak.

Recent Development

• In February 2020, Novo Nordisk had announced the launch of the long-acting recombinant factor VIII product named ESPEROCT. It used to prevent as well treat bleeding in individuals suffering from hemophilia A. The new therapy is generally used for routine prophylaxis, which further decreases bleeding episodes, on-demand treatment, control of bleeding episodes, and perioperative management of bleeding.

Global Hemophilia A Treatment Market Scope

The hemophilia A treatment market is segmented on the basis of type, product, demographic, treatment, diagnosis, therapy, drug class, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Severe
• Moderate
• Mild

Product

• Recombinant Factor Concentrates
  • Factor VIII
  • Factor IX
• Plasma-derived Factor Concentrates
  • Factor VIII
  • Factor IX
• Extended Half-life Products
  • Factor VIII
  • Factor IX

Demographic

• Pediatric
  • 0 to 4
  • 5 to 13
  • 14 to18
• Adult
  • 19 to 44
  • 45+

Diagnosis

• Genetic Testing
• Fibrinogen Test
• Factor VIII and Factor IX Tests
• Prothrombin Time (PT)
• Complete Blood Count (CBC)

Treatment

• Prophylaxis
• On Demand

Terapia

• Terapia de reemplazo de factores
• Terapia de reemplazo sin factores

Clase de droga

• Vasopresina
• Factores de coagulación

Forma de dosificación

• Inyección
• Soluciones
• Otros

Vía de administración

• Parenteral
• Aerosol nasal
• Otros

Usuarios finales

• Hospitales
• Clínicas de especialidades
• Cuidado domiciliario
• Otros

Canal de distribución

• Farmacia hospitalaria
• Farmacia minorista
• Farmacia en línea
• Otros

Análisis y perspectivas regionales del mercado de tratamiento de la hemofilia A

Se analiza el mercado de tratamiento de la hemofilia A y se proporcionan información y tendencias del tamaño del mercado por país, tipo, producto, demografía, tratamiento, diagnóstico, terapia, clase de fármaco, forma de dosificación, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.

Los países cubiertos en el informe del mercado de tratamiento de la hemofilia A son EE. UU., Canadá y México en América del Norte, Alemania, Francia, Reino Unido, Países Bajos, Suiza, Bélgica, Rusia, Italia, España, Turquía, Resto de Europa en Europa, China, Japón, India, Corea del Sur, Singapur, Malasia, Australia, Tailandia, Indonesia, Filipinas, Resto de Asia-Pacífico (APAC) en Asia-Pacífico (APAC), Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, Resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA), Brasil, Argentina y Resto de América del Sur como parte de América del Sur.

América del Norte domina el mercado de tratamiento de la hemofilia A en términos de participación de mercado e ingresos de mercado y seguirá fortaleciendo su dominio durante el período de pronóstico. Esto se debe a la presencia de actores clave importantes, y el aumento del gasto en atención médica impulsará aún más la tasa de crecimiento del mercado en esta región. Además, el aumento de las actividades de investigación y desarrollo impulsará aún más la tasa de crecimiento del mercado en esta región. 

Se espera que Asia-Pacífico crezca durante el período de pronóstico de 2022 a 2029 debido a la creciente aprobación de nuevas terapias para la hemofilia A en esta región. Además, el desarrollo de la infraestructura de atención médica y las crecientes iniciativas gubernamentales impulsarán aún más la tasa de crecimiento del mercado en esta región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado del tratamiento de la hemofilia A

El panorama competitivo del mercado de tratamiento de la hemofilia A proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de la hemofilia A.

Algunos de los principales actores que operan en el mercado del tratamiento de la hemofilia A son:

• Pfizer Inc. (Estados Unidos)
• GlaxoSmithKline plc (Reino Unido)
• Novartis AG (Suiza)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• AstraZeneca (Reino Unido)
• Johnson & Johnson Private Limited (Estados Unidos)
• Merck & Co., Inc. (Estados Unidos)
• F. Hoffmann-La Roche Ltd. (Suiza)
• Baxter (Estados Unidos)
• Takeda Pharmaceutical Company Limited (Japón)
• Grifols, SA (España)
• CSL (Estados Unidos)
• BioMarin (Estados Unidos)
• Spark Therapeutics, Inc. (Estados Unidos)
• Chugai Pharmaceutical Co. Ltd. (Japón)
• Octapharma AG (Suiza)
• Novo Nordisk A/S (Dinamarca)
• Biogen (Estados Unidos)
• Genentech Inc. (Estados Unidos)
• Bayer AG (Alemania)
• Ferring BV (Suiza)

SKU-56926